Elsevier adds 43 million enamine make-on-demand compounds to Reaxys to accelerate chemical research and development

By accessing Enamine’s novel compounds, Reaxys users can reduce development times and costs by up to 90%

London, United Kingdom–(Newsfile Corp. – December 3, 2024) – Elsevier, a global leader in information and analytics, and Enamine, a global leader in small molecules and early drug discovery services, have entered into a partnership to integrate Enamine announced database of over 43 million make-on-demand (MADE) analog connections in Reaxys. The integration will provide chemists with unprecedented access to a wide range of chemical compounds for accelerated drug development and materials science research.

Reaxys is a leading chemistry database that combines over one billion chemistry data points from scientific journals and patents with AI to support innovation in drug discovery, chemical R&D, and science. Combining Enamine’s expertise in compound synthesis with the extensive capabilities of the Reaxys platform, this new integration enables researchers to access an extensive archive of chemical information and facilitates the identification of new drug targets, biomarkers and screening compounds.

Enamine has a >70% success rate in generating novel, on-demand compounds and can typically synthesize compounds in two to six weeks. This helps chemists significantly accelerate the make phase of the design-make-test-analyze (DMTA) cycle, reducing development times and costs by up to 90%.

Mirit Eldor, Managing Director, Life Sciences Solutions at Elsevier, said: “Chemists across industries are under more pressure than ever to accelerate the development of novel and innovative products. Enamine’s high success rate has made it one of the most important suppliers of substances to Reaxys. By integrating the Enamine database into Reaxys, chemists gain access to millions of rapidly prepared novel analog compounds, giving them critical acceleration of the DMTA cycle Reaxys offers “It offers its customers the most up-to-date chemical database in the world.”

Enamine’s compounds are derived from Enamine MADE building blocks and Enamine REAL (REadily AccessibLe) screening compounds and prepared from stock reagents in 1-5 well-validated synthesis steps. Each compound is cataloged with detailed price and delivery time information, providing researchers with valuable insights to optimize their research processes.

Prof. Dr. Andrey Tolmachov, founder and CEO of Enamine, said: “Chemists face the decision to make or buy compounds every day. It is typically quicker and cheaper for chemists to purchase compounds than to make them themselves – so they need to be sure they are buying from a supplier with short delivery times and a high success rate. We are excited to integrate our database with Reaxys to give even more researchers access to compounds that can accelerate the discovery and development of transformative products.”

The collaboration is supported by Chemspace, an expert in generating and exploring extremely large chemical datasets. Chemspace will provide its infrastructure to streamline order fulfillment for Enamine.

Enamine’s compound database is now available to all Reaxys customers. For more information, see the Reaxys product page.

About Elsevier

As the world’s leading provider of scientific information and analysis, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We achieve this by enabling insights and critical decisions with innovative solutions based on trusted, evidence-based content and advanced AI-powered digital technologies.

We have been supporting the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, research and development-intensive companies, doctors, nurses, future healthcare professionals and educators in their important work. Our 2,900 scientific journals and well-known reference works include the leading titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation, we work with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analysis and decision-making tools for professional and business customers. Further information about our work, digital solutions and content can be found at www.elsevier.com.

About enamine

Enamine is a science-driven, integrated research contract research organization with unique partner opportunities in exploring new chemical areas. The company combines access to its proprietary screening compounds (4.4 million in stock) and building blocks (300,000 in stock) with a comprehensive platform of integrated research services to advance and accelerate drug discovery efforts.

Enamine MADE (MAke-on-DEmand) building blocks is a catalog of over 1 billion chemical building blocks synthesized in 1-5 steps with over 70 in a matter of weeks using pre-validated experience and starting materials from stock Enamine reagents can % success rate. For more information, visit: https://enamine.net/building-blocks/made-building-blocks

Enamine REAL contains trillions of synthetically viable molecules that can be synthesized extremely quickly (3-4 weeks), with high feasibility (over 80%) and inexpensively at Enamine. The REAL compounds are made through parallel chemistry by assembling 143,000 in-stock building blocks via 167 well-validated parallel synthesis protocols. This underlies Enamine’s approach to developing on-demand compounds to maximize the success rate of synthesis.

Both products, Enamine MADE Building Blocks and Enamine REAL Compounds, enable DMTA cycle shortening by rapidly delivering novel hit analogs, thereby accelerating discovery projects.

Media contact
Pragya Joshi
+44 7385 477880
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232162

Elsevier adds 43 million enamine make-on-demand compounds to Reaxys to accelerate chemical research and development

ByAmelia Journalton

By Amelia Journalton

Related Post

Ronaldo’s shocking Lee Kang in league is worse than the Saudi league.

What the Bengals’ Cade York said about the Browns after kicking a 59-yarder against his former team

The Chargers secure the spot by beating the Patriots

Leave a Reply Cancel reply

You missed

Ronaldo’s shocking Lee Kang in league is worse than the Saudi league.

What the Bengals’ Cade York said about the Browns after kicking a 59-yarder against his former team

The Chargers secure the spot by beating the Patriots

Trey Hendrickson’s case for Defensive Player of the Year: The Bengals’ unstoppable force in 2024